Proteome Regulatory News (PRM)

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Non-Executive Director

16 October, 2014 - The Board of Proteome Sciences is pleased to announce the appointment of Mr. Martin Diggle as a Non-Executive Director with immediate effect.

Mr. Diggle, 52, has worked in finance for over 30 years. He was a director and partner of UBS/Brunswick in Russia until 2003, following which he joined Vulpes Investment Management, where he is currently a director and partner. He is an experienced specialist investor in life sciences and manages the Vulpes Life Sciences Fund, the registered holder of 33,400,217 ordinary shares in Proteome Sciences representing approximately15.6% of the Company's ordinary share capital.

Mr. Diggle is currently a Non-Executive Director of Oxford Biomedica plc and Chronos Therapeutics Limited. Mr Diggle holds an M.A in Philosophy, Politics and Economics from Oxford University.

Save as disclosed above there is no further information required to be disclosed in accordance with paragraph (g) of Schedule 2 of the AIM Rules for companies,

- Ends -

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Executive Chairman

Dr. Ian Pike, Chief Operating Officer Tel: +44 (0)1932 865065

Geoff Ellis, Finance Director

Cenkos - Nominated Adviser

Stephen Keys/Mark Connelly/Callum Davidson Tel: +44 (0)20 7397 8900

finnCap - Joint Broker

Geoff Nash (Corporate Finance) Tel: +44 (0)20 7220 0500

Tony Quirke (Broking)

IKON Associates - Public Relations

Adrian Shaw Tel: +44 (0)1483 271291